The Centers for Medicare and Medicaid Services released on Tuesday the list of 10 medications that will be part of the price-setting Drug Price Negotiation Program through the Inflation Reduction Act, affecting an estimated 8.2 million patients with a range of illnesses, including heart failure, blood clots, diabetes, and arthritis.

The nonpartisan patient advocacy group, Survivors for Solutions, started by John “CZ” Czwartacki, a patient who has managed his MS for 30 years, provided a patient perspective on CMS’s drug price negotiation program talks this fall.

The nonpartisan patient advocacy group, Survivors for Solutions, started by John “CZ” Czwartacki, a patient who has managed his MS for 30 years, provided a patient perspective on CMS’s new coverage plan for Alzheimer’s drugs:

Minnesota is considering instituting an ill-conceived Prescription Drug Affordability Board (PDAB) over its state health care system, and the recent news of a state lawsuit against CVS brings more cause for concern.

Do you know that nightmare where you see someone about to get hurt or worse, but they don’t see the obvious danger? And your anguished pleas go unheard?

You wake from this frustrating helplessness, relieved it was just a dream.

Except, right now, I’m not waking up.

On April 11, Survivors For Solutions submitted a comment in the Federal Register criticizing the Centers for Medicare & Medicaid Services’ (CMS) implementation guidance for the Inflation Reduction Act’s (IRA) drug price negotiation program. This program would negatively impact medical innovation efforts and monumentally affect the patients with various illnesses and diseases downstream.